BMS at ACR Convergence 2021
Intended for U.S. scientific audiences only.
The American College of Rheumatology Convergence 2021 meeting (ACR Convergence 2021) is an important opportunity to review and share the latest research for patients living with immune-mediated rheumatic diseases.
Our Data at ACR Convergence 2021
Read more about our key data being presented at the meeting.
At ACR Convergence 2021, a total of 29 company-sponsored abstracts demonstrating the breadth and depth of the company’s robust rheumatology pipeline and portfolio will be presented. We continue to expand upon the foundation laid 20 years ago in rheumatoid arthritis, as we pursue pathbreaking science across other immune-mediated diseases such as psoriatic arthritis and lupus.
Our diverse, promising portfolio and pipeline is driven by our focus on offering innovative medicines that we hope will transform patients’ lives. Read about how our scientists are addressing some of the most challenging diseases of our time and advancing research across numerous immune-mediated diseases.
Shalabh Singhal, executive director, development program lead, Rheumatology, explains how by targeting the tyrosine kinase 2 (TYK2) pathway, researchers can further our understanding of how to improve care for psoriatic disease.
Our research in immunology and rheumatology spans a number of diseases and pathways. Learn more below.